Delving into the Latest Updates on Shanghai Jingshan Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

CAR-NK

Monoclonal antibody

Gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Hemic and Lymphatic Diseases	3
Immune System Diseases	2
Nervous System Diseases	1

Top 5 Drug Type	Count

CAR-NK	5
Gene therapy	1
Monoclonal antibody	1

Top 5 Target	Count

CD33 x CLL-1	2
KKLC1(Kita-Kyushu lung cancer antigen-1)	1
CD20(B-lymphocyte antigen CD20)	1
COL7A1(Collagen alpha-1(VII) chain)	1
EGFRvIII x EphA2 x HER2 x IL-13Rα2	1

主要目的：评价GCK-01细胞注射液在R/R FL患者中的安全性和耐受性。初步确定GCK-01细胞注射液的最大耐受剂量（MTD）或II期临床推荐剂量（RP2D）。次要目的：评估GCK-01细胞注射液在体内的药代动力学（PK）和药效动力学（PD）或其他生物标志物特征。初步评估GCK-01细胞注射液联合利妥昔单抗治疗R/R FL患者的有效性。

[Translation]

Primary Objective: To evaluate the safety and tolerability of GCK-01 cell injection in patients with R/R FL. To preliminarily determine the maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of GCK-01 cell injection. Secondary Objective: To evaluate the in vivo pharmacokinetics (PK) and pharmacodynamics (PD) of GCK-01 cell injection, or other biomarker characteristics. To preliminarily evaluate the efficacy of GCK-01 cell injection combined with rituximab in patients with R/R FL.

Start Date24 Nov 2025

Sponsor / Collaborator

Shanghai Jingshan Biotechnology Co., Ltd.

100 Clinical Results associated with Shanghai Jingshan Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Jingshan Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Jingshan Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Jingshan Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

2

Preclinical

IND Approval

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GCK-01 ( CD20 )	Refractory Follicular Lymphoma More	IND Approval
GC101 (Shanghai Jingshan) ( COL7A1 )	Epidermolysis Bullosa Dystrophica More	IND Approval
GCK-02.1 ( CD33 x CLL-1 )	Acute Myeloid Leukemia More	Preclinical
GCK-02.2 ( CD33 x CLL-1 )	Acute Myeloid Leukemia More	Preclinical
GCB-202 ( COL7A1 )	Epidermolysis Bullosa Dystrophica More	Discovery